Haibo Mou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haibo Mou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Shiqi Zhang
Department of Oncology, Shulan (Hangzhou) Hospital, Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China
2 shared publicationsBenfeng Xu
Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
1 shared publicationJianan Jin
Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
1 shared publication- Jianan Jin
Graduate School, Zhejiang Chinese Medical University, People's Republic of China
1 shared publication Qi Zheng
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publicationYibin Zhou
Graduate School, Zhejiang Chinese Medical University, Hangzhou, P.R. China
1 shared publication
Latest Publications
- Open Access
- 21 March 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1509458
The relationship between epigenetic biomarkers and the risk of diabetes and cancer: a machine learning modeling approach
Introduction: Epigenetic biomarkers are molecular indicators of epigenetic changes, and some studies have suggested that these biomarkers have predictive power for disease risk. This study aims to analyze the relationship between 30 epigenetic biomarkers and the risk of diabetes and cancer using machine learning modeling.Methods: The data for this study were sourced from the NHANES database, which includes DNA methylation arrays and epigenetic biomarker datasets. Nine machine learning algorithms were used to build models: AdaBoost, GBM, KNN, lightGBM, MLP, RF, SVM, XGBoost, and logistics. Model stability was evaluated using metrics such as Accuracy, MCC, and Sensitivity. The performance and decision-making ability of the models were displayed using ROC curves and DCA curves, while SHAP values were used to visualize the importance of each epigenetic biomarker.Results: Epigenetic age acceleration was strongly associated with cancer risk but had a weaker relationship with diabetes. In the diabetes model, the top three contributing features were logA1Mort, family income-to-poverty ratio, and marital status. In the cancer model, the top three contributing features were gender, non-Hispanic White ethnicity, and PACKYRSMort.Conclusion: Our study identified the relationship between epigenetic biomarkers and the risk of diabetes and cancer, and used machine learning techniques to analyze the contributions of various epigenetic biomarkers to disease risk.
- 21 March 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1509458
Open AccessThe relationship between epigenetic biomarkers and the risk of diabetes and cancer: a machine learning modeling approach
Introduction: Epigenetic biomarkers are molecular indicators of epigenetic changes, and some studies have suggested that these biomarkers have predictive power for disease risk. This study aims to analyze the relationship between 30 epigenetic biomarkers and the risk of diabetes and cancer using machine learning modeling.Methods: The data for this study were sourced from the NHANES database, which includes DNA methylation arrays and epigenetic biomarker datasets. Nine machine learning algorithms were used to build models: AdaBoost, GBM, KNN, lightGBM, MLP, RF, SVM, XGBoost, and logistics. Model stability was evaluated using metrics such as Accuracy, MCC, and Sensitivity. The performance and decision-making ability of the models were displayed using ROC curves and DCA curves, while SHAP values were used to visualize the importance of each epigenetic biomarker.Results: Epigenetic age acceleration was strongly associated with cancer risk but had a weaker relationship with diabetes. In the diabetes model, the top three contributing features were logA1Mort, family income-to-poverty ratio, and marital status. In the cancer model, the top three contributing features were gender, non-Hispanic White ethnicity, and PACKYRSMort.Conclusion: Our study identified the relationship between epigenetic biomarkers and the risk of diabetes and cancer, and used machine learning techniques to analyze the contributions of various epigenetic biomarkers to disease risk.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers
Background: Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma. Methods: This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves. Results: Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 vs ≥ 3.08, 95% CI: 1.864-9.624, P = 0.001), carcinoembryonic antigen (CEA <4.13 vs ≥ 4.13, 95% CI: 1.175-5.321, P = 0.017), and presence of bone metastasis (95% CI: 1.306-6.848, P = 0.010). The nomogram model achieved good predictive accuracy with a C-index of 0.811. CC indicated strong concordance between the predicted and observed outcomes. Multi-timepoint ROC curves at 1, 2, and 3 years validated the model’s performance (1-year AUC: 0.906, 2-year AUC: 0.832, 3-year AUC: 0.822). The multi-timepoint DCA curves also demonstrated a higher net benefit compared to extreme curves. Conclusion: The nomogram model, incorporating key risk factors for cholangiocarcinoma patients post-immune therapy, demonstrates robust predictive accuracy for survival outcomes, offering the potential for improved clinical decision-making.
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Open AccessNomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers
Background: Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma. Methods: This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves. Results: Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 vs ≥ 3.08, 95% CI: 1.864-9.624, P = 0.001), carcinoembryonic antigen (CEA <4.13 vs ≥ 4.13, 95% CI: 1.175-5.321, P = 0.017), and presence of bone metastasis (95% CI: 1.306-6.848, P = 0.010). The nomogram model achieved good predictive accuracy with a C-index of 0.811. CC indicated strong concordance between the predicted and observed outcomes. Multi-timepoint ROC curves at 1, 2, and 3 years validated the model’s performance (1-year AUC: 0.906, 2-year AUC: 0.832, 3-year AUC: 0.822). The multi-timepoint DCA curves also demonstrated a higher net benefit compared to extreme curves. Conclusion: The nomogram model, incorporating key risk factors for cholangiocarcinoma patients post-immune therapy, demonstrates robust predictive accuracy for survival outcomes, offering the potential for improved clinical decision-making.